Equities analysts expect Cancer Genetics Inc (NASDAQ:CGIX) to announce sales of $9.45 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Cancer Genetics’ earnings. The highest sales estimate is $9.90 million and the lowest is $9.00 million. Cancer Genetics reported sales of $7.23 million during the same quarter last year, which indicates a positive year over year growth rate of 30.7%. The company is scheduled to announce its next quarterly earnings results on Thursday, March 22nd.

According to Zacks, analysts expect that Cancer Genetics will report full year sales of $9.45 million for the current fiscal year, with estimates ranging from $30.17 million to $31.50 million. For the next financial year, analysts forecast that the business will post sales of $43.10 million per share, with estimates ranging from $37.70 million to $48.49 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Cancer Genetics.

Cancer Genetics (NASDAQ:CGIX) last released its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). Cancer Genetics had a negative return on equity of 46.21% and a negative net margin of 54.65%.

Several analysts have weighed in on CGIX shares. Maxim Group started coverage on Cancer Genetics in a report on Thursday, December 7th. They issued a “buy” rating and a $6.00 target price on the stock. ValuEngine lowered Cancer Genetics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. HC Wainwright set a $6.00 target price on Cancer Genetics and gave the company a “buy” rating in a report on Wednesday, November 29th. Finally, Zacks Investment Research lowered Cancer Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $5.56.

Cancer Genetics (NASDAQ:CGIX) traded down $0.05 during trading hours on Thursday, reaching $1.90. The company’s stock had a trading volume of 73,503 shares, compared to its average volume of 375,697. The stock has a market capitalization of $54.02, a PE ratio of -2.32 and a beta of 1.10. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01. Cancer Genetics has a 1 year low of $1.70 and a 1 year high of $5.30.

In other news, Director John Pappajohn bought 150,000 shares of the stock in a transaction on Friday, December 8th. The shares were bought at an average price of $1.86 per share, with a total value of $279,000.00. Following the completion of the acquisition, the director now owns 2,781,204 shares of the company’s stock, valued at $5,173,039.44. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 21.30% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp boosted its stake in shares of Cancer Genetics by 61.0% during the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after acquiring an additional 12,168 shares during the last quarter. Granahan Investment Management Inc. MA boosted its stake in shares of Cancer Genetics by 26.3% during the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after acquiring an additional 49,371 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Cancer Genetics by 61.9% during the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after acquiring an additional 197,619 shares during the last quarter. 11.13% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “$9.45 Million in Sales Expected for Cancer Genetics Inc (CGIX) This Quarter” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.dailypolitical.com/2018/01/21/9-45-million-in-sales-expected-for-cancer-genetics-inc-cgix-this-quarter.html.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Get a free copy of the Zacks research report on Cancer Genetics (CGIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.